Prosecution Insights
Last updated: August 16, 2026

Korro Bio Inc.

6 pending office actions • 3 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Portfolio Summary

6
Total Pending OAs
3
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
1
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 7 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (50%)
0
Medium (0%)
3
Easy (50%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only1 (17%)
Double-patenting only2 (33%)
Multi-statute (no §101)3 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
83% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
17% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
CHONG, KIMBERLY 1 72.4% +12.8%
SHIN, DANA H 1 27.0% +27.4%
LIPPOLIS, ALEXANDRA ROSE 1 39.3% +70.3%
MEYERING, SHABANA SHABBEER 1 69.7% +41.8%
DACE DENITO, ALEXANDRA GERALDINE 1 60.3% +35.7%
KONOPKA, CATHERINE ANNE 1 58.2% +64.5%

Hard Cases (4)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
17986014 METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) SHIN, DANA H 38d overdue
17986020 METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF OTOFERLIN (OTOF) DACE DENITO, ALEXANDRA GERALDINE 3d overdue
17985963 METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF GAP JUNCTION PROTEIN BETA 2 (GJB2) MEYERING, SHABANA SHABBEER 6d
17985970 METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF METHYL-CPG BINDING PROTEIN 2 (MECP2) LIPPOLIS, ALEXANDRA ROSE

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
17986014 METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) SHIN, DANA H 38d overdue
17986020 METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF OTOFERLIN (OTOF) DACE DENITO, ALEXANDRA GERALDINE 3d overdue
17985963 METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF GAP JUNCTION PROTEIN BETA 2 (GJB2) MEYERING, SHABANA SHABBEER 6d
18700152 METHODS AND COMPOSITIONS FOR DISRUPTING NRF2-KEAP1 PROTEIN INTERACTION BY ADAR MEDIATED RNA EDITING CHONG, KIMBERLY
17985970 METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF METHYL-CPG BINDING PROTEIN 2 (MECP2) LIPPOLIS, ALEXANDRA ROSE
17985974 METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF TRANSMEMBRANE CHANNEL-LIKE PROTEIN 1 (TMC1) KONOPKA, CATHERINE ANNE

Top Art Units

Art UnitApps
1635 3
1637 1
1636 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18700152 METHODS AND COMPOSITIONS FOR DISRUPTING NRF2-KEAP1 PROTEIN INTERACTION BY ADAR MEDIATED RNA EDITING CHONG, KIMBERLY §112 Non-Final OA Pending Apr 10, 2024
17986014 METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) SHIN, DANA H 1635 DP Final Rejection 38d overdue Pending Nov 14, 2022
17985970 METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF METHYL-CPG BINDING PROTEIN 2 (MECP2) LIPPOLIS, ALEXANDRA ROSE 1637 §102§103§112 Non-Final OA Pending Nov 14, 2022
17985963 METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF GAP JUNCTION PROTEIN BETA 2 (GJB2) MEYERING, SHABANA SHABBEER 1635 §102§103§112Other Final Rejection 6d Pending Nov 14, 2022
17986020 METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF OTOFERLIN (OTOF) DACE DENITO, ALEXANDRA GERALDINE 1636 §103§112Other Non-Final OA 3d overdue Pending Nov 14, 2022
17985974 METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF TRANSMEMBRANE CHANNEL-LIKE PROTEIN 1 (TMC1) KONOPKA, CATHERINE ANNE 1635 DP Final Rejection Pending Nov 14, 2022

Managing Korro Bio Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month